Amanda Bruno

669 total citations
49 papers, 494 citations indexed

About

Amanda Bruno is a scholar working on Cardiology and Cardiovascular Medicine, Economics and Econometrics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Amanda Bruno has authored 49 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cardiology and Cardiovascular Medicine, 10 papers in Economics and Econometrics and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amanda Bruno's work include Atrial Fibrillation Management and Outcomes (23 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Venous Thromboembolism Diagnosis and Management (8 papers). Amanda Bruno is often cited by papers focused on Atrial Fibrillation Management and Outcomes (23 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Venous Thromboembolism Diagnosis and Management (8 papers). Amanda Bruno collaborates with scholars based in United States, United Kingdom and Switzerland. Amanda Bruno's co-authors include Jeffrey Trocio, Melissa Lingohr-Smith, Jay Lin, Jack Mardekian, Xianying Pan, Hemant Phatak, Gregory Y.H. Lip, Cristina Masseria, Shital Kamble and Hugh Kawabata and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Amanda Bruno

46 papers receiving 485 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amanda Bruno United States 13 268 148 70 67 55 49 494
Anil Duggal United States 12 223 0.8× 149 1.0× 94 1.3× 20 0.3× 27 0.5× 27 452
Jonathan Seltzer United States 13 346 1.3× 80 0.5× 117 1.7× 56 0.8× 16 0.3× 30 546
Shijun Xia China 12 382 1.4× 43 0.3× 54 0.8× 47 0.7× 14 0.3× 46 553
A. Groth Germany 12 386 1.4× 117 0.8× 53 0.8× 67 1.0× 13 0.2× 25 626
Winfried Haerer Germany 8 211 0.8× 65 0.4× 113 1.6× 25 0.4× 44 0.8× 29 346
Mattias Wieloch Sweden 13 424 1.6× 157 1.1× 27 0.4× 32 0.5× 8 0.1× 33 536
Ashley Chen United States 5 302 1.1× 194 1.3× 54 0.8× 13 0.2× 43 0.8× 10 440
Wael Al Mahmeed United Arab Emirates 12 396 1.5× 81 0.5× 69 1.0× 35 0.5× 7 0.1× 39 529
D R Jones United Kingdom 6 95 0.4× 75 0.5× 54 0.8× 76 1.1× 40 0.7× 9 332
Federica Agnello Italy 12 247 0.9× 48 0.3× 158 2.3× 16 0.2× 29 0.5× 27 422

Countries citing papers authored by Amanda Bruno

Since Specialization
Citations

This map shows the geographic impact of Amanda Bruno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda Bruno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda Bruno more than expected).

Fields of papers citing papers by Amanda Bruno

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda Bruno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda Bruno. The network helps show where Amanda Bruno may publish in the future.

Co-authorship network of co-authors of Amanda Bruno

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda Bruno. A scholar is included among the top collaborators of Amanda Bruno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda Bruno. Amanda Bruno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rider, Jennifer R., Asher Wasserman, Gillis Carrigan, et al.. (2024). Emulations of oncology trials using real-world data: a systematic literature review. American Journal of Epidemiology. 194(6). 1783–1793. 1 indexed citations
2.
3.
Bridgewater, John, Xiaolong Jiao, Clare Flach, et al.. (2022). Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project. Cancer Treatment and Research Communications. 33. 100623–100623. 6 indexed citations
4.
5.
Lip, Gregory Y.H., Xianying Pan, Shital Kamble, et al.. (2016). Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States. International Journal of Clinical Practice. 70(9). 752–763. 93 indexed citations
6.
Lip, Gregory Y.H., Allison Keshishian, Shital Kamble, et al.. (2016). REAL WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS NEWLY INITIATED ON APIXABAN, WARFARIN, DABIGATRAN OR RIVAROXABAN: A 1:1 PROPENSITY-SCORE MATCHED ANALYSIS. Journal of the American College of Cardiology. 67(13). 882–882. 7 indexed citations
7.
Shafrin, Jason, Amanda Bruno, Joanna P. MacEwan, et al.. (2016). Physician and Patient Preferences for Nonvalvular Atrial Fibrillation Therapies. Value in Health. 19(4). 451–459. 14 indexed citations
8.
9.
Amin, Alpesh, Amanda Bruno, Jeffrey Trocio, Jay Lin, & Melissa Lingohr-Smith. (2015). Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States. Journal of Managed Care & Specialty Pharmacy. 21(10). 965–972. 10 indexed citations
10.
Deitelzweig, Steven, Michael A. Evans, Eric Hillson, et al.. (2015). DOES WARFARIN TIME-IN-THERAPEUTIC RANGE AFFECT HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG NONVALVULAR ATRIAL FIBRILLATION PATIENTS IN THE U.S.?. Journal of the American College of Cardiology. 65(10). A1515–A1515. 1 indexed citations
11.
Farr, Amanda M., Yonghua Jing, Stephen S. Johnston, et al.. (2015). Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin. Hospital Practice. 43(3). 172–179. 13 indexed citations
12.
An, Jaejin, Fang Niu, Nazia Rashid, et al.. (2015). Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice. Journal of the American Heart Association. 4(7). 16 indexed citations
13.
Amin, Alpesh, Amanda Bruno, Jeffrey Trocio, Jay Lin, & Melissa Lingohr-Smith. (2015). Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. Journal of Medical Economics. 18(6). 399–409. 26 indexed citations
14.
Amin, Alpesh, Amanda Bruno, Jeffrey Trocio, Jeffrey Lin, & Melissa Lingohr-Smith. (2015). Estimated savings in medical costs when new oral anticoagulants are used for the treatment of patients with nonvalvular atrial fibrillation and venous thromboembolism vs. Warfarin in the u.s. Value in Health. 18(3). A138–A138. 1 indexed citations
15.
Deitelzweig, Steve, Michael A. Evans, Eric Hillson, et al.. (2015). Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation. Current Medical Research and Opinion. 32(1). 87–94. 8 indexed citations
16.
An, Jaejin, Fang Niu, Nazia Rashid, et al.. (2014). TIME IN THERAPEUTIC RANGE ≥55% VERSUS <55% ON WARFARIN THERAPY OUTCOMES IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS. Journal of the American College of Cardiology. 63(12). A359–A359. 1 indexed citations
17.
Centis, Elena, Marina Trento, Alessandra Dei, et al.. (2014). Stage of change and motivation to healthy diet and habitual physical activity in type 2 diabetes. Acta Diabetologica. 51(4). 559–566. 37 indexed citations
18.
Sikirica, Vanja, Moshe Fridman, Amanda Bruno, Paul Hodgkins, & M. Haim Erder. (2013). Concomitant Pharmacotherapy of Psychotropic Medications in EU Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Drugs in R&D. 13(4). 271–280. 12 indexed citations
19.
Feinberg, Bruce A., et al.. (2012). Hemoglobin Trends and Anemia Treatment Resulting From Concomitant Chemotherapy in Community Oncology Clinics. Journal of Oncology Practice. 8(1). 18–23. 8 indexed citations
20.
Gruden, Gabriella, et al.. (1992). Albumin excretion rate in non diabetic offspring of type 2 diabetic patients. 35. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anil Duggal Breakdown of academic impact, for papers by Jonathan Seltzer Breakdown of academic impact, for papers by Shijun Xia Breakdown of academic impact, for papers by A. Groth Breakdown of academic impact, for papers by Winfried Haerer Breakdown of academic impact, for papers by Mattias Wieloch Breakdown of academic impact, for papers by Ashley Chen Breakdown of academic impact, for papers by Wael Al Mahmeed Breakdown of academic impact, for papers by D R Jones Breakdown of academic impact, for papers by Federica Agnello
Rankless by CCL
2026